Published by Coherent Market Insights
Posted on October 8, 2021
GLP-1 Receptor Agonist market is expected to reach US$ 19,253.8 Mn by 2028 from US$ 12,720.6 Mn in 2020, at a CAGR of 6.1%. The base year considered for the study is 2020 and the forecast period 2021-2028.
GLP-1 receptor (Glucagon like peptide-1 receptor) is a receptor protein found in the neurons of the brain and the beta cells of pancreas. GLP-1 receptor is involved in regulating the process of insulin secretion in the body. GLP-1 and glucagon are the natural endogenous agonists of GLP-1 receptor. An agonist is a chemical entity which induces a biological response by binding to a receptor and activating it. Some of the other agonists of GLP-1 receptor include exenatide, lixisenatide, albiglutide, liraglutide, dulaglutide, and semaglutide. GLP-1 receptor agonists are commonly used for the treatment of diabetes and obesity. When an agonist binds to the GLP-1 receptor the receptor becomes activated and results in stimulation of adenylyl cyclase pathway. Adenylyl cyclase pathway leads to increased production and release of insulin in the beta cells of pancreas. GLP-1 receptors expressed in the brain neurons are responsible for controlling appetite. GLP-1 receptor is also expressed in stretch responsive sensory neurons of the stomach and intestines. These GLP-1 receptor neurons, when activated can cause changes in the breathing and heart rate. GLP-1 receptor agonists, also known as incretin mimetics, are advantageous over traditional insulin secretagogues, such as sulfonylureas or meglitinides as they pose a low risk of causing hypoglycemia or low blood sugar.
Request Sample GLP-1 Receptor Agonist market Report @
https://www.coherentmarketinsights.com/insight/request-sample/4632
Key players operating in the market are focusing on submitting application for the approval of drugs therapy for the treatment of diabetes and obesity, which is expected to drive growth of the global GLP-1 receptor agonist market during the forecast period.
For instance, in April 2020, Novo Nordisk A/S, a Denmark-based pharmaceutical company, received marketing authorization approval from European Medicines Agency (EMA) for its drug, Rybelsus (semaglutide) which is an oral GLP-1 receptor agonist indicated for the treatment of Type-2 diabetic people.
Moreover, in July 2020, 9 Meters Biopharma, Inc., a U.S.-based clinical-stage rare gastroenterology company, announced that the company had initiated Phase 1b/2a clinical trial to assess the efficacy and safety of its drug candidate NM-002, a glucagon-like peptide-1 (GLP-1) receptor agonist in adults with short bowel syndrome (SBS). Short Bowel Syndrome is a rare gastrointestinal disease caused by a significant shortening of the gastrointestinal tract, resulting in impairment of nutrient absorption. NM-002 is an injectable designed to treat gastric motility in short bowel syndrome patients by slowing emptying time of stomach’s digestive juices.
Furthermore, in September 2020, Eli Lilly and Company, a U.S.-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for two additional doses of its GLP-1 receptor agonist drug, Trulicity (dulaglutide). Trulicity is indicated for treatment of adults suffering from type-2 diabetes.
Ask for PDF sample GLP-1 Receptor Agonist market report @
https://www.coherentmarketinsights.com/insight/request-pdf/4632
The objectives of this study are as follows:
To define, describe, and forecast the global GLP-1 Receptor Agonist market by product & service, technique, design, application, end user, and region
To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for the key players
To forecast the size of the market with respect to five regions: North America, Europe, Asia Pacific, and the Rest of the World
To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
To track and analyze competitive developments in the GLP-1 Receptor Agonist market, such as agreements, collaborations, acquisitions, product launches, expansions, and R&D activities
• Data regarding the industry share by every item fragment, alongside their reasonable worth, have been served in the report.
• We provide statistic information, strategic and analysis tool results to provide a sophisticated landscape and target key market players.
• Our report helps readers decipher the current and future constraints of the market and optimal business strategies to enhance market development.
• Our reports have been examined by professional experts of the industry, which makes them beneficial for the company to maximize their return on investment.
• The analysis acknowledges that the sector players & key drivers of both conflicts and growth assess the impact of limitations as well as the opportunities on the sector.
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/4632
Available Customizations
With the given market data, Coherent Market Insights offers customizations as per the company‘s specific needs.
The following customization options are available for this report.
This report segments the GLP-1 Receptor Agonist market into product & service, technique, design, application, end user, and region. Based on products & services, the market is segmented into test kits and testing services. In 2020, the test kits segment accounted for the largest share of the total market. The growing demand for GLP-1 Receptor Agonist in research as well as diagnostics to understand the genetic variability of chronic disorders is propelling the growth of this GLP-1 Receptor Agonist market segment.
Based on design, the GLP-1 Receptor Agonist market is segmented into predesigned and customized panels. The customized GLP-1 Receptor Agonist segment is expected grow at the highest CAGR during the forecast period. This growth is attributed to the evolving needs of the emerging therapeutic and diagnostic application sectors and the increasing number of clinical and preclinical research studies.
The GLP-1 Receptor Agonist market is fragmented with the presence of several small and big players. Prominent players in this market include Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, PegBio Co., Ltd., AstraZeneca, Intarcia Therapeutics, Inc., Amylin Pharmaceuticals, Inc., Sanofi, Hanmi Pharm. Co., Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., and 9 Meters Biopharma, Inc.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post GLP-1 Receptor Agonist Market to See Booming Develop Rapidly | Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk A/S appeared first on Gatorledger.
GLP-1 Receptor Agonist market is expected to reach US$ 19,253.8 Mn by 2028 from US$ 12,720.6 Mn in 2020, at a CAGR of 6.1%. The base year considered for the study is 2020 and the forecast period 2021-2028.
GLP-1 receptor (Glucagon like peptide-1 receptor) is a receptor protein found in the neurons of the brain and the beta cells of pancreas. GLP-1 receptor is involved in regulating the process of insulin secretion in the body. GLP-1 and glucagon are the natural endogenous agonists of GLP-1 receptor. An agonist is a chemical entity which induces a biological response by binding to a receptor and activating it. Some of the other agonists of GLP-1 receptor include exenatide, lixisenatide, albiglutide, liraglutide, dulaglutide, and semaglutide. GLP-1 receptor agonists are commonly used for the treatment of diabetes and obesity. When an agonist binds to the GLP-1 receptor the receptor becomes activated and results in stimulation of adenylyl cyclase pathway. Adenylyl cyclase pathway leads to increased production and release of insulin in the beta cells of pancreas. GLP-1 receptors expressed in the brain neurons are responsible for controlling appetite. GLP-1 receptor is also expressed in stretch responsive sensory neurons of the stomach and intestines. These GLP-1 receptor neurons, when activated can cause changes in the breathing and heart rate. GLP-1 receptor agonists, also known as incretin mimetics, are advantageous over traditional insulin secretagogues, such as sulfonylureas or meglitinides as they pose a low risk of causing hypoglycemia or low blood sugar.
Request Sample GLP-1 Receptor Agonist market Report @
https://www.coherentmarketinsights.com/insight/request-sample/4632
Key players operating in the market are focusing on submitting application for the approval of drugs therapy for the treatment of diabetes and obesity, which is expected to drive growth of the global GLP-1 receptor agonist market during the forecast period.
For instance, in April 2020, Novo Nordisk A/S, a Denmark-based pharmaceutical company, received marketing authorization approval from European Medicines Agency (EMA) for its drug, Rybelsus (semaglutide) which is an oral GLP-1 receptor agonist indicated for the treatment of Type-2 diabetic people.
Moreover, in July 2020, 9 Meters Biopharma, Inc., a U.S.-based clinical-stage rare gastroenterology company, announced that the company had initiated Phase 1b/2a clinical trial to assess the efficacy and safety of its drug candidate NM-002, a glucagon-like peptide-1 (GLP-1) receptor agonist in adults with short bowel syndrome (SBS). Short Bowel Syndrome is a rare gastrointestinal disease caused by a significant shortening of the gastrointestinal tract, resulting in impairment of nutrient absorption. NM-002 is an injectable designed to treat gastric motility in short bowel syndrome patients by slowing emptying time of stomach’s digestive juices.
Furthermore, in September 2020, Eli Lilly and Company, a U.S.-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for two additional doses of its GLP-1 receptor agonist drug, Trulicity (dulaglutide). Trulicity is indicated for treatment of adults suffering from type-2 diabetes.
Ask for PDF sample GLP-1 Receptor Agonist market report @
https://www.coherentmarketinsights.com/insight/request-pdf/4632
The objectives of this study are as follows:
To define, describe, and forecast the global GLP-1 Receptor Agonist market by product & service, technique, design, application, end user, and region
To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for the key players
To forecast the size of the market with respect to five regions: North America, Europe, Asia Pacific, and the Rest of the World
To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
To track and analyze competitive developments in the GLP-1 Receptor Agonist market, such as agreements, collaborations, acquisitions, product launches, expansions, and R&D activities
• Data regarding the industry share by every item fragment, alongside their reasonable worth, have been served in the report.
• We provide statistic information, strategic and analysis tool results to provide a sophisticated landscape and target key market players.
• Our report helps readers decipher the current and future constraints of the market and optimal business strategies to enhance market development.
• Our reports have been examined by professional experts of the industry, which makes them beneficial for the company to maximize their return on investment.
• The analysis acknowledges that the sector players & key drivers of both conflicts and growth assess the impact of limitations as well as the opportunities on the sector.
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/4632
Available Customizations
With the given market data, Coherent Market Insights offers customizations as per the company‘s specific needs.
The following customization options are available for this report.
This report segments the GLP-1 Receptor Agonist market into product & service, technique, design, application, end user, and region. Based on products & services, the market is segmented into test kits and testing services. In 2020, the test kits segment accounted for the largest share of the total market. The growing demand for GLP-1 Receptor Agonist in research as well as diagnostics to understand the genetic variability of chronic disorders is propelling the growth of this GLP-1 Receptor Agonist market segment.
Based on design, the GLP-1 Receptor Agonist market is segmented into predesigned and customized panels. The customized GLP-1 Receptor Agonist segment is expected grow at the highest CAGR during the forecast period. This growth is attributed to the evolving needs of the emerging therapeutic and diagnostic application sectors and the increasing number of clinical and preclinical research studies.
The GLP-1 Receptor Agonist market is fragmented with the presence of several small and big players. Prominent players in this market include Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, PegBio Co., Ltd., AstraZeneca, Intarcia Therapeutics, Inc., Amylin Pharmaceuticals, Inc., Sanofi, Hanmi Pharm. Co., Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., and 9 Meters Biopharma, Inc.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post GLP-1 Receptor Agonist Market to See Booming Develop Rapidly | Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk A/S appeared first on Gatorledger.
Explore more articles in the Research Reports category
